Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Michael Gibson C, et al. Among authors: yee m. Circulation. 2016 Dec 13;134(24):1918-1930. doi: 10.1161/CIRCULATIONAHA.116.025687. Epub 2016 Nov 15. Circulation. 2016. PMID: 27881559 Free PMC article. Clinical Trial.
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. Gibson CM, et al. Among authors: yee mk. Am Heart J. 2019 Feb;208:81-90. doi: 10.1016/j.ahj.2018.11.008. Epub 2018 Nov 22. Am Heart J. 2019. PMID: 30580130 Clinical Trial.
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.
Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ. Nafee T, et al. Among authors: yee mk. Circulation. 2019 Feb 26;139(9):1234-1236. doi: 10.1161/CIRCULATIONAHA.118.038654. Circulation. 2019. PMID: 30802169 No abstract available.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Gibson CM, et al. Among authors: yee mk. Am Heart J. 2021 Jan;231:121-127. doi: 10.1016/j.ahj.2020.10.052. Epub 2020 Oct 13. Am Heart J. 2021. PMID: 33065120 Free article.
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Gibson CM, et al. Among authors: yee m. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Circulation. 2017. PMID: 27881555 Free PMC article. Clinical Trial.
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT; APEX Investigators. Gibson CM, et al. Among authors: yee mk. Am Heart J. 2017 Mar;185:93-100. doi: 10.1016/j.ahj.2016.12.004. Epub 2016 Dec 18. Am Heart J. 2017. PMID: 28267480 Clinical Trial.
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Chi G, et al. Circulation. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187. Circulation. 2018. PMID: 29279341 Clinical Trial. No abstract available.
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.
Gibson CM, Jennings LK, Chi G, Yee MK, Halaby R, Nafee T, AlKhalfan F, Kerneis M, Korjian S, Daaboul Y, Goldhaber SZ, Hull RD, Hernandez AF, Cohen AT, Harrington RA. Gibson CM, et al. Among authors: yee mk. TH Open. 2018 Jan 8;2(1):e16-e24. doi: 10.1055/s-0037-1615288. eCollection 2018 Jan. TH Open. 2018. PMID: 31249924 Free PMC article.
469 results